1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
PHS 2024-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required) (NIDA Participation) is sponsored by National Institute on Drug Abuse (NIDA). NIDA participates in this omnibus solicitation for Small Business Innovation Research (SBIR) grant applications, supporting PI-initiated research with potential for technology commercialization and public health impact related to drug use and addiction.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
A **. gov** website belongs to an official government organization in the United States.
* How to Apply for Grants * **Applicant Resources** * Adobe Software Compatibility * Submitting UTF-8 Special Characters * Encountering Error Messages * Grantor Standard Language * Submitting UTF-8 Special Characters * **Applicant System-To-System** * Reference Implementation * **Grantor System-To-System** * Reference Implementation * SF-424 Individual Family * SF-424 Mandatory Family * SF-424 Short Organization Family * Post-Award Reporting Forms * Country and State Lists Updates * **Manage Subscriptions** * Program Management Office * Grants.
gov Maintenance Calendar PHS 2024-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed) Department of Health and Human Services National Institutes of Health Document Type:Grants Notice Funding Opportunity Number:PA-24-245 Funding Opportunity Title:PHS 2024-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed) Opportunity Category:Discretionary Opportunity Category Explanation: Funding Instrument Type:Grant Category of Funding Activity:Education Income Security and Social Services Expected Number of Awards: Assistance Listings:93.
113 -- Environmental Health 93. 121 -- Oral Diseases and Disorders Research 93. 142 -- NIEHS Hazardous Waste Worker Health and Safety Training 93.
143 -- NIEHS Superfund Hazardous Substances_Basic Research and Education 93. 172 -- Human Genome Research 93. 173 -- Research Related to Deafness and Communication Disorders 93.
213 -- Research and Training in Complementary and Integrative Health 93. 233 -- National Center on Sleep Disorders Research 93. 242 -- Mental Health Research Grants 93.
273 -- Alcohol Research Programs 93. 279 -- Drug Abuse and Addiction Research Programs 93. 286 -- Discovery and Applied Research for Technological Innovations to Improve Human Health 93.
307 -- Minority Health and Health Disparities Research 93. 350 -- National Center for Advancing Translational Sciences 93. 351 -- Research Infrastructure Programs 93.
361 -- Nursing Research 93. 393 -- Cancer Cause and Prevention Research 93. 394 -- Cancer Detection and Diagnosis Research 93.
395 -- Cancer Treatment Research 93. 837 -- Cardiovascular Diseases Research 93. 838 -- Lung Diseases Research 93.
839 -- Blood Diseases and Resources Research 93. 840 -- Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders 93. 846 -- Arthritis, Musculoskeletal and Skin Diseases Research 93.
847 -- Diabetes, Digestive, and Kidney Diseases Extramural Research 93. 853 -- Extramural Research Programs in the Neurosciences and Neurological Disorders 93. 855 -- Allergy and Infectious Diseases Research 93.
859 -- Biomedical Research and Research Training 93. 865 -- Child Health and Human Development Extramural Research 93. 867 -- Vision Research 93.
879 -- Medical Library Assistance Cost Sharing or Matching Requirement:No Last Updated Date:Apr 01, 2025 Original Closing Date for Applications:Apr 05, 2025 Current Closing Date for Applications:Sep 05, 2025 Archive Date:Oct 05, 2025 Estimated Total Program Funding: Eligible Applicants:Small businesses Additional Information on Eligibility:Other Eligible Applicants include the following:Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
## Additional Information Agency Name:National Institutes of Health Description:This Notice of Funding Opportunity (NOFO), issued by the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA), invites eligible United States small businesses to submit Small Business Innovation Research (SBIR) grant applications.
United States small businesses that have the research capabilities and technological expertise to contribute to the R and D mission(s) of the NIH, CDC, and FDA awarding components identified in this NOFO are encouraged to submit SBIR grant applications in response to identified topics (see SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA).
This Parent Funding Opportunity Announcement does not accept clinical trials. Link to Additional Information:https://grants. nih.
gov/grants/guide/pa-files/PA-24-245. html Grantor Contact Information:If you have difficulty accessing the full announcement electronically, please contact: See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
#### Health & Human Services * Frequently Asked Questions ## Your session will expire in 3 minutes. To continue working, click on the "OK" button below. This is being done to protect your privacy.
Unsaved changes will be lost.
According to the current listing, eligibility includes: Small business concerns (SBCs). Confirm the full requirements in the official notice before applying.
The current listing shows normally may not exceed $306,872 for Phase I, and $2,045,816 for Phase II, unless proposal fall under one of the approved topics. Verify award ceilings, matching requirements, and allowable costs in the official notice.
PHS 2024-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required) (NIDA Participation) is funded by National Institute on Drug Abuse (NIDA). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articleARPA-H's FASTPASS program targets a public-health blind spot: substandard and contaminated drugs that are only caught after patients are exposed. It funds through-package chemical sensing (TA1 SAMPLE) and the analytics to act on it (TA2 DETECT). The solicitation posts to SAM.gov in mid-August 2026, with a virtual Proposer Workshop on August 24 and registration closing August 20. Here is what FASTPASS funds, why the timing matters, and how to position a cross-disciplinary team.
Read articleARPA-H PROSPR program funds seven research teams testing rapamycin, semaglutide, and novel compounds to extend healthspan. A deep analysis of the science, the money, and what it means for the field.
Read article